Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), KRAS inhibitors(GTPase KRas inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | CA | 09 Apr 2024 | |
Triple Negative Breast Cancer | Preclinical | CA | 09 Apr 2024 |